Chronic allograft nephropathy: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
Tags: mobile edit mobile web edit
 
Line 1: Line 1:
{{SI}}
{{Infobox medical condition
| name                    = Chronic allograft nephropathy
| image                  = [[File:Chronic_allograft_nephropathy_-_intermed_mag.jpg|250px]]
| caption                = Histopathological image of chronic allograft nephropathy
| field                  = [[Nephrology]]
| synonyms                = Chronic rejection, chronic transplant nephropathy
| symptoms                = [[Hypertension]], [[proteinuria]], progressive [[renal failure]]
| complications          = [[End-stage renal disease]]
| onset                  = Months to years post-transplant
| duration                = Chronic
| causes                  = Immune-mediated injury, [[ischemia]], [[nephrotoxicity]]
| risks                  = [[Acute rejection]], [[delayed graft function]], [[immunosuppressive therapy]]
| diagnosis              = [[Biopsy]], [[serum creatinine]] levels, [[urinalysis]]
| differential            = [[Acute rejection]], [[recurrent disease]], [[drug toxicity]]
| treatment              = [[Immunosuppressive therapy]], [[antihypertensive drugs]], [[dietary modification]]
| prognosis              = Variable, often leads to [[graft loss]]
| frequency              = Common in long-term transplant recipients
}}
'''Chronic Allograft Nephropathy (CAN)''' is a medical condition affecting the kidneys after a [[Kidney transplantation|kidney transplant]]. It is characterized by a gradual loss of kidney function and is considered a leading cause of long-term graft failure. The term "chronic allograft nephropathy" has been largely replaced by the term "interstitial fibrosis and tubular atrophy" (IFTA) without specific etiology, as it more accurately describes the histological findings seen in these patients.
'''Chronic Allograft Nephropathy (CAN)''' is a medical condition affecting the kidneys after a [[Kidney transplantation|kidney transplant]]. It is characterized by a gradual loss of kidney function and is considered a leading cause of long-term graft failure. The term "chronic allograft nephropathy" has been largely replaced by the term "interstitial fibrosis and tubular atrophy" (IFTA) without specific etiology, as it more accurately describes the histological findings seen in these patients.
==Causes==
==Causes==
The exact cause of CAN is multifactorial and includes both immunologic and non-immunologic factors. Immunologic factors involve the recipient's immune response against the transplanted kidney, including acute and chronic rejection episodes. Non-immunologic factors include drug toxicity (especially from calcineurin inhibitors), hypertension, diabetes, and infections.
The exact cause of CAN is multifactorial and includes both immunologic and non-immunologic factors. Immunologic factors involve the recipient's immune response against the transplanted kidney, including acute and chronic rejection episodes. Non-immunologic factors include drug toxicity (especially from calcineurin inhibitors), hypertension, diabetes, and infections.
==Symptoms==
==Symptoms==
Symptoms of CAN are often nonspecific and can include a gradual decrease in kidney function, as evidenced by increased serum creatinine levels, decreased glomerular filtration rate (GFR), hypertension, and proteinuria. In many cases, symptoms may not become apparent until significant kidney damage has occurred.
Symptoms of CAN are often nonspecific and can include a gradual decrease in kidney function, as evidenced by increased serum creatinine levels, decreased glomerular filtration rate (GFR), hypertension, and proteinuria. In many cases, symptoms may not become apparent until significant kidney damage has occurred.
==Diagnosis==
==Diagnosis==
Diagnosis of CAN involves a combination of clinical assessment, laboratory tests, and histological evaluation of kidney tissue obtained through a biopsy. The biopsy is crucial for distinguishing CAN from acute rejection and other potential causes of kidney dysfunction post-transplantation.
Diagnosis of CAN involves a combination of clinical assessment, laboratory tests, and histological evaluation of kidney tissue obtained through a biopsy. The biopsy is crucial for distinguishing CAN from acute rejection and other potential causes of kidney dysfunction post-transplantation.
==Treatment==
==Treatment==
Treatment of CAN is challenging and focuses on slowing the progression of the disease. This may involve adjustments in immunosuppressive therapy, management of blood pressure and proteinuria, and addressing any modifiable risk factors such as diabetes and obesity. In cases where graft function continues to decline, dialysis or re-transplantation may be necessary.
Treatment of CAN is challenging and focuses on slowing the progression of the disease. This may involve adjustments in immunosuppressive therapy, management of blood pressure and proteinuria, and addressing any modifiable risk factors such as diabetes and obesity. In cases where graft function continues to decline, dialysis or re-transplantation may be necessary.
==Prevention==
==Prevention==
Preventive strategies for CAN include careful selection of donor and recipient, optimal management of immunosuppression to minimize drug toxicity while preventing rejection, and aggressive management of risk factors such as hypertension and diabetes.
Preventive strategies for CAN include careful selection of donor and recipient, optimal management of immunosuppression to minimize drug toxicity while preventing rejection, and aggressive management of risk factors such as hypertension and diabetes.
==Prognosis==
==Prognosis==
The prognosis for patients with CAN varies. Early detection and intervention can slow the progression of the disease, but many patients eventually experience graft loss and return to dialysis or undergo a second transplant.
The prognosis for patients with CAN varies. Early detection and intervention can slow the progression of the disease, but many patients eventually experience graft loss and return to dialysis or undergo a second transplant.
[[Category:Kidney diseases]]
[[Category:Kidney diseases]]
[[Category:Transplantation medicine]]
[[Category:Transplantation medicine]]
{{Transplant-stub}}
{{Transplant-stub}}
<gallery>
File:Chronic_allograft_nephropathy_-_intermed_mag.jpg
</gallery>

Latest revision as of 02:07, 5 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Chronic allograft nephropathy
Synonyms Chronic rejection, chronic transplant nephropathy
Pronounce N/A
Specialty N/A
Symptoms Hypertension, proteinuria, progressive renal failure
Complications End-stage renal disease
Onset Months to years post-transplant
Duration Chronic
Types N/A
Causes Immune-mediated injury, ischemia, nephrotoxicity
Risks Acute rejection, delayed graft function, immunosuppressive therapy
Diagnosis Biopsy, serum creatinine levels, urinalysis
Differential diagnosis Acute rejection, recurrent disease, drug toxicity
Prevention N/A
Treatment Immunosuppressive therapy, antihypertensive drugs, dietary modification
Medication N/A
Prognosis Variable, often leads to graft loss
Frequency Common in long-term transplant recipients
Deaths N/A


Chronic Allograft Nephropathy (CAN) is a medical condition affecting the kidneys after a kidney transplant. It is characterized by a gradual loss of kidney function and is considered a leading cause of long-term graft failure. The term "chronic allograft nephropathy" has been largely replaced by the term "interstitial fibrosis and tubular atrophy" (IFTA) without specific etiology, as it more accurately describes the histological findings seen in these patients.

Causes[edit]

The exact cause of CAN is multifactorial and includes both immunologic and non-immunologic factors. Immunologic factors involve the recipient's immune response against the transplanted kidney, including acute and chronic rejection episodes. Non-immunologic factors include drug toxicity (especially from calcineurin inhibitors), hypertension, diabetes, and infections.

Symptoms[edit]

Symptoms of CAN are often nonspecific and can include a gradual decrease in kidney function, as evidenced by increased serum creatinine levels, decreased glomerular filtration rate (GFR), hypertension, and proteinuria. In many cases, symptoms may not become apparent until significant kidney damage has occurred.

Diagnosis[edit]

Diagnosis of CAN involves a combination of clinical assessment, laboratory tests, and histological evaluation of kidney tissue obtained through a biopsy. The biopsy is crucial for distinguishing CAN from acute rejection and other potential causes of kidney dysfunction post-transplantation.

Treatment[edit]

Treatment of CAN is challenging and focuses on slowing the progression of the disease. This may involve adjustments in immunosuppressive therapy, management of blood pressure and proteinuria, and addressing any modifiable risk factors such as diabetes and obesity. In cases where graft function continues to decline, dialysis or re-transplantation may be necessary.

Prevention[edit]

Preventive strategies for CAN include careful selection of donor and recipient, optimal management of immunosuppression to minimize drug toxicity while preventing rejection, and aggressive management of risk factors such as hypertension and diabetes.

Prognosis[edit]

The prognosis for patients with CAN varies. Early detection and intervention can slow the progression of the disease, but many patients eventually experience graft loss and return to dialysis or undergo a second transplant.


   This article is a transplant stub. You can help WikiMD by expanding it!